Conventional T cells, while highly potent effector cells in immune surveillance and destruction of malignant cells, exhibit inherent functional constraints that impact CAR-T therapy outcomes. Factors such as exhaustion after repeated antigen stimulation, limited persistence, and the immunosuppressive tumor microenvironment dampen their sustained anti-tumor activity. Moreover, limitations in trafficking to tumor sites, issues with cytokine release syndrome, and the risk of graft-versus-host disease in allogeneic CAR-T treatments add further complexity. The manufacturing process itself, which typically involves autologous T cell collection, genetic modification, and expansion, is time-consuming, costly, and often results in products with variable quality and efficacy.

In response to these challenges, scientific efforts have increasingly turned towards harnessing the unique properties of immune cells beyond conventional αβ T cells. This strategy, broadly designated as “CAR-X” cell engineering, leverages the diverse biology of alternative immune populations such as natural killer (NK) cells, invariant natural killer T (iNKT) cells, γδ T cells, and macrophages. Each of these cell types possesses distinct functional attributes that may complement or surpass the capabilities of traditional CAR-T cells. Consequently, CAR-X therapies promise to enhance clinical efficacy, reduce side effects, and enable applications across a broader spectrum of diseases including solid tumors, infectious diseases, and autoimmune disorders.

Natural killer cells, for instance, play a vital role in innate immunity through their ability to recognize and eliminate virally infected or transformed cells without prior sensitization. Their intrinsic cytotoxicity and cytokine secretion profiles endow them with rapid effector functions. Notably, NK cells display a reduced risk of causing graft-versus-host disease, making them attractive candidates for allogeneic “off-the-shelf” CAR therapies. However, the limited in vivo persistence and challenges in genetic modification have historically hindered their development. Advances in gene editing and culture conditions are addressing these issues, enabling the generation of CAR-NK products with improved longevity and potent tumor-killing capacities.

Invariant natural killer T cells combine features of both innate and adaptive immunity with their semi-invariant T cell receptors recognizing glycolipid antigens presented by CD1d molecules. This unique biology allows iNKT cells to modulate the immune microenvironment profoundly, not only attacking tumor cells directly but also stimulating other immune effectors and overcoming immunosuppression. Engineering CARs into iNKT cells leverages these dual functionalities, offering a multifaceted therapeutic approach. Furthermore, iNKT cells exhibit lower alloreactivity, suggesting a safer profile for allogenic therapies.

Similarly, γδ T cells represent a distinct T cell lineage characterized by their γδ T cell receptors, which recognize stress-induced ligands independent of major histocompatibility complex (MHC) presentation. This property confers several advantages, including broad tumor recognition and the ability to function in an immunosuppressive milieu. CAR-γδ T cells can exploit these features to target cancers resistant to conventional therapies while benefiting from innate-like recognition pathways that limit immune escape. Ongoing innovations in ex vivo expansion and genetic engineering techniques are enabling scalable production of CAR-γδ T cell products.

Macrophages, traditionally viewed as phagocytic cells involved in tissue homeostasis and inflammation, are emerging as compelling vectors for CAR therapy due to their natural tumor infiltration and antigen-presenting capabilities. CAR-macrophages can potentially engulf and destroy tumor cells directly and orchestrate robust antitumor immune responses by activating adaptive immunity. Moreover, they can be engineered to remodel the tumor microenvironment, counteracting immune evasion mechanisms. Despite technical challenges in genetic modification and expansion, recent breakthroughs in viral and non-viral transduction methodologies have propelled CAR-macrophage development forward.

The design of CAR constructs tailored specifically to each immune cell type is another critical frontier in CAR-X engineering. Conventional CARs optimized for αβ T cells may not fully harness the unique signaling pathways and functional mechanisms of alternative immune cells. For example, CARs in NK cells often incorporate signaling domains derived from activating NK receptors like NKG2D or DAP12 to promote-specific activation, while CARs for macrophages integrate phagocytosis-inducing domains. Fine-tuning CAR architecture to synergize with endogenous signaling can substantially enhance efficacy and persistence within the host.

Manufacturing platforms are also evolving to accommodate the cell-specific requirements of CAR-X therapies. Whereas CAR-T cell production typically relies on lentiviral or retroviral transduction of T cells collected via leukapheresis, alternative approaches such as non-viral gene editing, mRNA electroporation, and stem cell differentiation protocols are being adapted. These tailored manufacturing strategies aim to improve scalability, safety profiles, and the timely generation of clinical-grade CAR-X products. Additionally, the potential to create universal donor cell banks using gene editing to prevent rejection or graft-versus-host disease presents a paradigm shift toward ready-to-use allogeneic cell therapies.

From a clinical perspective, early-phase trials integrating CAR-NK, CAR-iNKT, and CAR-γδ T cells have demonstrated encouraging safety profiles and preliminary efficacy signals, particularly in refractory hematological malignancies. The intrinsic biology of these cells contributes to attenuated cytokine release syndromes and neurotoxicity, which are common adverse events in CAR-T therapy. Moreover, solid tumor targeting, a notorious hurdle for CAR-T cells, may be more achievable with CAR-X cells due to their distinct trafficking and tissue-infiltrating capabilities. Accordingly, the clinical landscape is rapidly expanding, encompassing hematologic cancers, solid malignancies, viral infections, and even fibrotic or autoimmune diseases.

Despite these exciting developments, significant challenges remain in translating CAR-X technologies into widely available therapies. The heterogeneity of alternative immune cells necessitates optimization in expansion, persistence, and potency to achieve consistent therapeutic responses. Immune evasion by tumors, antigen heterogeneity, and immune suppression continue to pose obstacles that demand combinatorial or multifunctional engineering strategies. Concurrently, regulatory frameworks must adapt to the complexity of these novel therapies to ensure safety without stifling innovation.

In summary, CAR-X cell engineering represents a transformative frontier in immunotherapy, leveraging the diversity of the immune system to overcome the constraints of conventional CAR-T approaches. By harnessing the unique effector mechanisms and biological properties of NK cells, iNKT cells, γδ T cells, macrophages, and potentially other immune subsets, this paradigm expansion is poised to unlock new avenues for treating cancer and beyond. The iterative refinement of cell-specific CAR designs, manufacturing methods, and clinical applications heralds a future where personalized, effective, and safer cellular therapies redefine medicine.

As research accelerates, collaborations between academic institutions, biotechnology companies, and regulatory agencies will be paramount in propelling CAR-X therapies from experimental stages to mainstream clinical use. Integrative efforts that combine multi-omic profiling, machine learning, and synthetic biology will undoubtedly yield next-generation CAR constructs and cell products with enhanced functionality. In concert, ongoing clinical trials will illuminate the therapeutic landscape, refining indications, dosing regimens, and combination approaches to optimize patient outcomes.

Ultimately, the story of CAR-X cell engineering is one of innovation driven by the limitations of prior successes, a testament to the relentless pursuit of harnessing the immune system’s vast potential. The next decade promises to be pivotal, with the envisioned convergence of diverse immune cell engineering shaping a new chapter in immunotherapy that extends hope to millions of patients worldwide.

Subject of Research: Development and application of alternative immune cells engineered with chimeric antigen receptors (CAR-X) for enhanced immunotherapy.

Article Title: CAR-X cell engineering.

Article References:
Li, X., Lin, H., Liang, J. et al. CAR-X cell engineering. Nat Rev Bioeng (2026). https://doi.org/10.1038/s44222-026-00430-w

Glioblastoma’s resistance to current therapies has long been attributed in large part to its immunosuppressive microenvironment, which severely limits the infiltration, survival, and function of therapeutic T cells. Traditional CAR T cell therapies that have demonstrated remarkable success against hematological malignancies face formidable obstacles when targeting solid tumors like glioblastoma. The lack of sustained T cell activation and the prevalence of exhaustion phenotypes contribute to their diminished efficacy. Addressing this formidable challenge, the research team exploited a gene therapy approach that genetically engineers hematopoietic progenitor cells to produce monocytes and macrophages capable of selectively releasing immunostimulatory cytokines upon tumor infiltration.

This precision delivery system utilizes a dual-cytokine strategy within the TME. Interferon-alpha (IFN-α), known for its multifaceted immune-enhancing properties, counters immunosuppressive cues, improves antigen presentation, and amplifies the activity of immune effector cells. Concurrently, an engineered mutation of interleukin-2 (IL-2) selectively activates a mutated receptor expressed exclusively on the administered CAR T cells, ensuring that only these therapeutic cells receive proliferative signals without triggering systemic toxicities. The co-expression of this mutant IL-2 receptor and the mutant cytokine creates a private, tumor-confined signaling axis that fine-tunes the immune response.

The study employed murine models that faithfully recapitulate human glioblastoma pathophysiology and immunological barriers, enabling comprehensive evaluation of the therapeutic paradigm. In these models, CAR T cells administered alone demonstrated minimal antitumor effects, mirroring clinical trial outcomes where CAR T cells have struggled to control solid tumors. However, when combined with tumor-targeted cytokine delivery, the CAR T cells exhibited restored functional potency, resulting in pronounced delays in tumor growth and significant improvements in survival. Notably, the antitumor response extended even to tumors with heterogeneous antigen expression, suggesting that the approach transcends single antigen targeting by enlisting endogenous T cells through a mechanism known as antigenic spreading.

Antigenic spreading is a critical immune phenomenon whereby an initial immune response against a specific tumor antigen broadens to include additional tumor-associated antigens. This results in a more robust and comprehensive antitumor immunity capable of counteracting tumor immune evasion strategies. The researchers found that IFN-α played a pivotal role in orchestrating this process by reshaping the TME into an immune-stimulatory milieu that recruits and activates the host’s own T cell populations alongside the engineered CAR T cells. This cooperative engagement of multiple immune cell subsets provides a promising foundation for durable tumor control.

Central to the approach is the reprogramming of tumor-associated macrophages, which are ordinarily contributors to the immunosuppressive environment. By incorporating genes encoding the cytokines under tight regulatory control into hematopoietic progenitors, the resulting macrophages deliver the immunostimulatory payload directly within the tumor niche. This localized cytokine release modifies the TME and facilitates a conducive environment for CAR T cell persistence and activation. The spatial precision of this cytokine delivery minimizes systemic exposure, thereby reducing the risk of adverse effects that have hampered previous systemic cytokine therapies.

The concept of private cytokine cross-talk established in this study represents a paradigm shift in immunotherapy. Rather than systemic administration of immune stimulants—which often result in dose-limiting toxicities and off-target effects—this method confines cytokine activity to the precise cellular players and anatomical location implicated in antitumor immunity. According to co-first author Dr. Alvisi, this targeted interaction “ensures that immune stimulants act only where needed, sparing the rest of the body from systemic toxicity, and specifically on the relevant target cells involved in tumor attack.”

This research also builds on the prior success of the gene therapy platform now implemented in a first-in-human clinical trial, the Temferon trial (NCT03866109), conducted by Genenta Science, a biotech spin-off originating from the San Raffaele Institute. Temferon leverages the selective delivery of IFN-α to glioblastoma lesions as a stand-alone treatment, demonstrating feasibility, safety, and preliminary biological activity in human subjects. While early results highlight promising modulation of the tumor microenvironment and hints of therapeutic benefit, the intrinsic limitations of a phase 1 study with a small patient cohort warrant further exploration into combination strategies.

The present study’s demonstration that coupling the Temferon approach with CAR T cell therapy potentiates antitumor efficacy opens exciting avenues for clinical translation. By broadening the therapeutic arsenal against glioblastoma, this combinatory strategy could overcome the historical resistance encountered by cellular immunotherapies targeting solid tumors. The robust engagement of endogenous T cells and the generation of a more permissive microenvironment underscore the potential to combat tumor heterogeneity and immune escape alike.

The implications of this work extend beyond glioblastoma, providing a blueprint for integrating gene therapy-driven macrophage reprogramming with engineered T cell therapies across diverse solid tumor indications. It exemplifies a sophisticated interplay between cellular therapies and localized gene delivery systems to coax the immune system into mounting a potent and selective antitumor response. Such convergence of technologies might redefine therapeutic paradigms in oncology, pushing the boundaries of what is achievable with precision immunotherapy.

Luigi Naldini, Director of SR-TIGET, remarks, “This work represents another important step forward in our decade-long commitment to develop novel gene and cell therapy strategies effective against tumors… A combination of Temferon with CAR T cell administration, as prompted by our new study, could in future further enhance the benefit of the treatment and broaden its efficacy.” This sentiment captures the transformative potential of bridging innovative genetic engineering with advanced cellular therapies to tackle one of the most challenging malignancies known to medicine.

In conclusion, the study presented by the SR-TIGET team delivers a compelling demonstration of how tumor-targeted cytokine delivery can rescue CAR T cell function and orchestrate a coordinated antitumor immune response in glioblastoma. By constructing a private cytokine communication channel within the tumor, the therapy not only revitalizes CAR T cells but also mobilizes broad host immunity, marking a significant stride toward effective immunotherapeutics in solid cancers. The journey from genetic engineering of progenitors to clinical translation exemplifies the power of integrative science to innovate in the fight against cancer, inspiring hope for patients and clinicians alike facing the daunting prognosis of glioblastoma.

Subject of Research: Immunotherapy, Gene Therapy, Glioblastoma, CAR T Cells, Tumor Microenvironment, Cytokine Delivery

Article Title: A cross-talk established by tumor-targeted cytokines rescues CAR T cell activity and engages host T cells against glioblastoma in mice

News Publication Date: 2-Jul-2025

Web References:

• DOI: 10.1126/scitranslmed.ado9511
• Temferon Trial: NCT03866109
• San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET): https://research.hsr.it/en/institutes/san-raffaele-telethon-institute-for-gene-therapy.html
• Genenta Science: https://www.genenta.com/

Image Credits: San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET)

Keywords: Glioblastoma, CAR T Cells, Gene Therapy, Cytokines, Tumor Microenvironment, IFN-α, Interleukin-2, Macrophage Reprogramming, Immune Cross-talk, Antigenic Spreading, Temferon, Solid Tumor Immunotherapy